Urelumab

Urelumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	CD137
Clinical data
Other names	BMS-663513
ATC code	none;
Identifiers
CAS Number	934823-49-1 ;
ChemSpider	none;
UNII	230902QLLC;
KEGG	D09984;
Chemical and physical data
Formula	C6502H9972N1712O2030S44
Molar mass	146015.89 g·mol−1
	(what is this?)

Urelumab (BMS-663513 or anti-4-1BB antibody) is a fully human IgG4 monoclonal antibody developed by Bristol-Myers Squibb for the treatment of cancer and solid tumors.^[1]

Urelumab targets the extracellular domain of CD137.^[2] It specifically binds to and activates CD137-expressing immune cells, stimulating an immune response, in particular a cytotoxic T cell response, against tumor cells.^[3]

The first phase I trial began in 2006 and final results were published in 2015.^[4]

Current clinical trials combine urelumab with chemotherapy (NCT00351325), chemoradiation (NCT00461110), ipilimumab (NCT00803374), rituximab (NCT01775631, NCT02420938), cetuximab (NCT02110082), and elotuzumab (NCT02252263), nivolumab (NCT02253992) for metastatic solid tumors, NSCLC, melanoma, B-cell non-Hodgkin lymphoma, colorectal cancer, and multiple myeloma. A biomarker study using CyTOF is also underway.^[2]

References[]

^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Urelumab" (PDF). American Medical Association.
^ ^a ^b Yonezawa A, Dutt S, Chester C, Kim J, Kohrt HE (July 2015). "Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy". Clinical Cancer Research. 21 (14): 3113–20. doi:10.1158/1078-0432.CCR-15-0263. PMC 5422104. PMID 25908780.
^ "Urelumab". National Cancer Institute.
^ Clinical trial number NCT00309023 for "Study of BMS-663513 in Patients With Advanced Cancer" at ClinicalTrials.gov

This monoclonal antibody–related article is a stub. You can help Wikipedia by .

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by .

[1] "Statement On A Nonproprietary Name Adopted By The USAN Council: Urelumab" (PDF). American Medical Association.

[:0-2] Yonezawa A, Dutt S, Chester C, Kim J, Kohrt HE (July 2015). "Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy". Clinical Cancer Research. 21 (14): 3113–20. doi:10.1158/1078-0432.CCR-15-0263. PMC 5422104. PMID 25908780.

[3] "Urelumab". National Cancer Institute.

[4] Clinical trial number NCT00309023 for "Study of BMS-663513 in Patients With Advanced Cancer" at ClinicalTrials.gov

[1]

[2]

[3]

[4]